Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010:95:201-210.
doi: 10.1159/000315953. Epub 2010 Jun 1.

Anaphylaxis: acute treatment and management

Review

Anaphylaxis: acute treatment and management

Johannes Ring et al. Chem Immunol Allergy. 2010.

Abstract

Anaphylaxis is the maximal variant of an acute life-threatening immediate-type allergy. Due to its often dramatic onset and clinical course, practical knowledge in the management of these reactions is mandatory both for physicians and patients. It has to be distinguished between acute treatment modalities and general recommendations for management of patients who have suffered from an anaphylactic reaction. Acute treatment comprises general procedures like positioning, applying an intravenous catheter, call for help, comfort of the patient as well as the application of medication. The acute treatment modalities are selected depending upon the intensity of the clinical symptomatology as they are categorized in 'severity grades'. First of all it is important to diagnose anaphylaxis early and consider several differential diagnoses. This diagnosis is purely clinical and laboratory tests are of no help in the acute situation. Epinephrine is the essential antianaphylactic drug in the pharmacologic treatment. It should be first applied intramuscularly, only in very severe cases or under conditions of surgical interventions intravenous application can be tried. Furthermore, glucocorticosteroids are given in order to prevent protracted or biphasic courses of anaphylaxis; they are of little help in the acute treatment. Epinephrine autoinjectors can be used by the patient him/herself. Histamine H(1)-antagonists are valuable in mild anaphylactic reactions; they should be given intravenously if possible. The replacement of volume is crucial in antianaphylactic treatment. Crystalloids can be used in the beginning, in severe shock colloid volume substitutes have to be applied. Patients suffering from an anaphylactic episode should be observed over a period of 4-10 h according to the severity of the symptomatology. It is crucial to be aware or recognize risk patients as for example patients with severe uncontrolled asthma, or under beta-adrenergic blockade. When bronchial symptoms are in the focus, inhaled beta(2)-agonists can be tried, also for laryngeal edema. The use of combined H(1)- and H(2)-antagonists has been recommended for prophylaxis prior to application of potentially anaphylaxis-eliciting drugs (e.g. radiographic contrast media). Patients who have survived an anaphylactic reaction have to be thoroughly examined and an allergy diagnosis has to be performed with regard to the eliciting agent and the pathogenic mechanism involved. In cases of clear-cut IgE-mediated anaphylaxis, allergen-specific immunotherapy is available for some allergens and helpful as for example for insect venom anaphylaxis. Furthermore, patients should be trained with regard to the nature of anaphylaxis, the major eliciting agents and the principles of behavior and coping with the situation including the handling of epinephrine autoinjectors and the application of antianaphylactic medication. Educational programs for anaphylaxis have been developed.

PubMed Disclaimer

Similar articles

  • Anaphylaxis.
    Simons FE. Simons FE. J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S161-81. doi: 10.1016/j.jaci.2009.12.981. J Allergy Clin Immunol. 2010. PMID: 20176258 Review.
  • [Emergency treatment and management of anaphylaxis].
    Brockow K, Ring J. Brockow K, et al. Hautarzt. 2013 Feb;64(2):81-7. doi: 10.1007/s00105-012-2453-5. Hautarzt. 2013. PMID: 23385622 Review. German.
  • Management of Anaphylaxis.
    Navalpakam A, Thanaputkaiporn N, Poowuttikul P. Navalpakam A, et al. Immunol Allergy Clin North Am. 2022 Feb;42(1):65-76. doi: 10.1016/j.iac.2021.09.005. Immunol Allergy Clin North Am. 2022. PMID: 34823751 Review.
  • Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis.
    Shaker MS, Wallace DV, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, Dinakar C, Ellis A, Greenhawt M, Khan DA, Lang DM, Lang ES, Lieberman JA, Portnoy J, Rank MA, Stukus DR, Wang J; Collaborators; Riblet N, Bobrownicki AMP, Bontrager T, Dusin J, Foley J, Frederick B, Fregene E, Hellerstedt S, Hassan F, Hess K, Horner C, Huntington K, Kasireddy P, Keeler D, Kim B, Lieberman P, Lindhorst E, McEnany F, Milbank J, Murphy H, Pando O, Patel AK, Ratliff N, Rhodes R, Robertson K, Scott H, Snell A, Sullivan R, Trivedi V, Wickham A; Chief Editors; Shaker MS, Wallace DV; Workgroup Contributors; Shaker MS, Wallace DV, Bernstein JA, Campbell RL, Dinakar C, Ellis A, Golden DBK, Greenhawt M, Lieberman JA, Rank MA, Stukus DR, Wang J; Joint Task Force on Practice Parameters Reviewers; Shaker MS, Wallace DV, Golden DBK, Bernstein JA, Dinakar C, Ellis A, Greenhawt M, Horner C, Khan DA, Lieberman JA, Oppenheimer J, Rank MA, Shaker MS, Stukus DR, Wang J. Shaker MS, et al. J Allergy Clin Immunol. 2020 Apr;145(4):1082-1123. doi: 10.1016/j.jaci.2020.01.017. Epub 2020 Jan 28. J Allergy Clin Immunol. 2020. PMID: 32001253
  • Guidance on Completing a Written Allergy and Anaphylaxis Emergency Plan.
    Wang J, Sicherer SH; SECTION ON ALLERGY AND IMMUNOLOGY. Wang J, et al. Pediatrics. 2017 Mar;139(3):e20164005. doi: 10.1542/peds.2016-4005. Epub 2017 Feb 13. Pediatrics. 2017. PMID: 28193793

Cited by

MeSH terms

LinkOut - more resources